Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PASG | 8-K | bullish | 8/10 | Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, w | Sep 3, 2026 |
| GILD | CLUSTER | neutral | 2/10 | GILD insiders, including Chairman & CEO Daniel O'Day and Director Anthony Welters, sold a total of ~$921K in open-market | Sep 3, 2026 |
| OCUL | CLUSTER | neutral | 4/10 | Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief | Sep 3, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen and Eisai announced that China's NMPA approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) f | Sep 3, 2026 |
| CAMP | CLUSTER | neutral | 3/10 | Camp4 Therapeutics Corp (CAMP) insider trading cluster shows a mixed pattern: Director Andrew Schwab sold 400,000 shares | Sep 2, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Two C-suite insiders at Nurix Therapeutics (NRIX), Chief Scientific Officer Gwenn Hansen and Chief Legal Officer Christi | Sep 2, 2026 |
| RARE | 8-K | bearish | 8/10 | Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the pri | Sep 2, 2026 |
| GLMD | 6-K | neutral | 2/10 | Galmed Pharmaceuticals filed a 6-K reporting that its Annual General Meeting of Shareholders, convened on September 2, 2 | Sep 2, 2026 |
| SCTX | 8-K | bullish | 7/10 | Scribe Therapeutics reported Q2 2026 results: net loss of $6.5M ($2.62/share) vs. $9.9M loss ($4.08/share) a year ago, o | Sep 2, 2026 |
| PVLA | 144 | neutral | 2/10 | Director Christopher Kiritsy filed a Form 144 notice of intent to sell 375 shares of Palvella Therapeutics, valued at ap | Sep 2, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund XII, L.P., a venture capital insider, filed a Form 144 notice of intent to sell 513 shares of Disc Me | Sep 2, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex Life Sciences Corp. (AVXL) announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing | Sep 2, 2026 |
| MAZE | 144 | neutral | 2/10 | Two officers of Maze Therapeutics filed Form 144 notices on September 2, 2026, indicating intent to sell shares to satis | Sep 2, 2026 |
| GNLX | CLUSTER | bearish | 5/10 | Three top executives at GENELUX Corp, the CEO, CSO, and CTO, sold a combined $147K in open-market sales on August 31, 20 | Sep 2, 2026 |
| JAZZ | CLUSTER | bearish | 4/10 | A cluster of insider selling at Jazz Pharmaceuticals totals $6.01M in open-market sales over a 7-day window. The largest | Sep 2, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences (CEO, COO, CCO) sold a total of $373K in open-market transactions over a on | Sep 2, 2026 |
| SCTX | PRESS-RELEASE | bullish | 7/10 | Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9M (down 61% YoY from $4.9M) and a net loss of $6.5M ($ | Sep 2, 2026 |
| ATTO | PRESS-RELEASE | bullish | 7/10 | Attovia Therapeutics reported Q2 2026 results with a net loss of $20.7M (vs $14.4M in Q2 2025) and minimal collaboration | Sep 2, 2026 |
| TARS | 144 | bearish | 4/10 | Former officer Aziz Mottiwala filed a Form 144 to sell 8,000 shares (~$654k) of Tarsus Pharmaceuticals. This follows sub | Sep 2, 2026 |
| REX | 8-K | bullish | 7/10 | REX American Resources reported a record fiscal Q2 2026 with diluted EPS of $1.06 vs $0.22 a year ago, on revenue of $16 | Sep 2, 2026 |
| CANF | 6-K | bullish | 6/10 | Can-Fite BioPharma announced that blinded overall survival in its ongoing Phase III Namodenoson study for advanced hepat | Sep 2, 2026 |
| QURE | 8-K | bullish | 7/10 | uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gen | Sep 2, 2026 |
| TOMZ | 8-K | mixed | 6/10 | TOMI Environmental Solutions reported that holders of $2,475,000 in convertible notes converted their notes into 1,649,9 | Sep 2, 2026 |
| PPBT | 6-K | neutral | 3/10 | Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods | Sep 2, 2026 |
| RAJAF | 6-K | bearish | 6/10 | TFA Therapeutics disclosed an offshore private placement of up to 5,952,381 ordinary shares at $2.52/share, targeting up | Sep 2, 2026 |
| CANF | 6-K | mixed | 5/10 | Can-Fite BioPharma announced the immediate exercise of outstanding warrants for approximately $4.0 million in gross proc | Sep 2, 2026 |
| CANF | PRESS-RELEASE | bearish | 6/10 | Can-Fite BioPharma announced a warrant exercise agreement to raise ~$4.0M gross proceeds by immediately exercising 1,591 | Sep 2, 2026 |
| CALC | 8-K | bearish | 6/10 | CalciMedica resolved its Nasdaq MVLS deficiency by qualifying under the alternative stockholders' equity standard (repor | Sep 2, 2026 |
| ALLO | 8-K | neutral | 3/10 | Allogene Therapeutics disclosed the retirement of EVP and CFO Geoffrey Parker, effective November 6, 2026. No replacemen | Sep 2, 2026 |
| TCRX | 8-K | bearish | 7/10 | TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, termination of its CFO and C | Sep 2, 2026 |